Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0435 plus platinum and etoposide in extensive-stage small cell lung cancer
CTR20230318Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HTMC0435 in small cell lung cancer (SCLC) (3 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoints: Dose-limiting toxicities and adverse events of HTMC0435 in combination with platinum and etoposide, Maximum tolerated dose and recommended phase 2 dose of HTMC0435 in combination with platinum and etoposide and 3 more. Started Apr 2023; status: active.
02
Drugs
HTMC0435
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20230318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230318.